243 related articles for article (PubMed ID: 33420019)
21. Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells.
Zhang M; Truscott J; Davie J
Mol Cancer; 2013 Nov; 12(1):150. PubMed ID: 24279793
[TBL] [Abstract][Full Text] [Related]
22. TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells.
Zhu B; Zhang M; Byrum SD; Tackett AJ; Davie JK
Int J Cancer; 2014 Aug; 135(4):785-97. PubMed ID: 24470334
[TBL] [Abstract][Full Text] [Related]
23. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
[TBL] [Abstract][Full Text] [Related]
24. Mutation of Thr115 in MyoD positively regulates function in murine fibroblasts and human rhabdomyosarcoma cells.
Liu LN; Dias P; Houghton PJ
Cell Growth Differ; 1998 Sep; 9(9):699-711. PubMed ID: 9751114
[TBL] [Abstract][Full Text] [Related]
25. A SNAI2/CTCF Interaction is Required for
Sreenivas P; Wang L; Wang M; Challa A; Modi P; Hensch NR; Gryder B; Chou HC; Zhao XR; Sunkel B; Moreno-Campos R; Khan J; Stanton BZ; Ignatius MS
Mol Cell Biol; 2023; 43(11):547-565. PubMed ID: 37882064
[TBL] [Abstract][Full Text] [Related]
26. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
[TBL] [Abstract][Full Text] [Related]
27. AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell.
Jothi M; Nishijo K; Keller C; Mal AK
Cell Cycle; 2012 Mar; 11(5):895-908. PubMed ID: 22333587
[TBL] [Abstract][Full Text] [Related]
28. Actin-related protein 5 functions as a novel modulator of MyoD and MyoG in skeletal muscle and in rhabdomyosarcoma.
Morita T; Hayashi K
Elife; 2022 Mar; 11():. PubMed ID: 35348112
[TBL] [Abstract][Full Text] [Related]
29. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
30. TWIST2-mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma.
Shah AM; Guo L; Morales MG; Jaichander P; Chen K; Huang H; Cano Hernandez K; Xu L; Bassel-Duby R; Olson EN; Liu N
Sci Adv; 2023 Apr; 9(17):eade8184. PubMed ID: 37115930
[TBL] [Abstract][Full Text] [Related]
31. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.
Crose LE; Galindo KA; Kephart JG; Chen C; Fitamant J; Bardeesy N; Bentley RC; Galindo RL; Chi JT; Linardic CM
J Clin Invest; 2014 Jan; 124(1):285-96. PubMed ID: 24334454
[TBL] [Abstract][Full Text] [Related]
32. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW
J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049
[TBL] [Abstract][Full Text] [Related]
33. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH; Mercado GE; Laé M; Ladanyi M
Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
[TBL] [Abstract][Full Text] [Related]
34. A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
Hüttner SS; Henze H; Elster D; Koch P; Anderer U; von Eyss B; von Maltzahn J
Mol Ther; 2023 Sep; 31(9):2612-2632. PubMed ID: 37452493
[TBL] [Abstract][Full Text] [Related]
35.
Kendall GC; Watson S; Xu L; LaVigne CA; Murchison W; Rakheja D; Skapek SX; Tirode F; Delattre O; Amatruda JF
Elife; 2018 Jun; 7():. PubMed ID: 29869612
[TBL] [Abstract][Full Text] [Related]
36. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
37. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
[TBL] [Abstract][Full Text] [Related]
38. The deubiquitinase USP7 and E3 ligase TRIM21 regulate vasculogenic mimicry and malignant progression of RMS by balancing SNAI2 homeostasis.
Zhang R; Zhang D; Han F; Song X; Zhang Y; Zhang J; Zhu Q; Qin Y
J Exp Clin Cancer Res; 2024 May; 43(1):135. PubMed ID: 38702792
[TBL] [Abstract][Full Text] [Related]
39. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation.
Marchesi I; Fiorentino FP; Rizzolio F; Giordano A; Bagella L
Cell Cycle; 2012 Oct; 11(20):3828-36. PubMed ID: 22983009
[TBL] [Abstract][Full Text] [Related]
40. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]